001     838511
005     20231023125112.0
024 7 _ |2 Handle
|a 2128/17599
037 _ _ |a FZJ-2017-07103
100 1 _ |0 P:(DE-Juel1)132024
|a Strodel, Birgit
|b 0
|e Corresponding author
245 _ _ |a Learning from simulations
260 _ _ |c 2017
336 7 _ |2 DataCite
|a Text
336 7 _ |0 PUB:(DE-HGF)4
|2 PUB:(DE-HGF)
|a Communication
|b comm
|m comm
|s 1520582817_31514
336 7 _ |2 BibTeX
|a MISC
336 7 _ |2 ORCID
|a OTHER
336 7 _ |2 DINI
|a Other
336 7 _ |0 4
|2 EndNote
|a Personal Communication
500 _ _ |a Pan European Networks: Health 02: 91-92
520 _ _ |a Alzheimer’s disease (AD) is the most common form ofdementia in the elderly. Currently, one in eight persons abovethe age of 65 is suffering from this disorder and it is expectedthat there will be 100 million persons affected by 2040. In AD, thesmall molecular weight amyloid-ß peptide (Aß) has been identifiedas a clinical hallmark in disease development and progression.
536 _ _ |0 G:(DE-HGF)POF3-553
|a 553 - Physical Basis of Diseases (POF3-553)
|c POF3-553
|f POF III
|x 0
856 4 _ |u http://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=07dcafa0-b8b5-4a5d-b3d1-cbd8f366eeab
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.pdf
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.gif?subformat=icon
|x icon
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.jpg?subformat=icon-1440
|x icon-1440
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/838511/files/PEN.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:838511
|p openaire
|p open_access
|p OpenAPC
|p driver
|p VDB
|p openCost
910 1 _ |0 I:(DE-588b)5008462-8
|6 P:(DE-Juel1)132024
|a Forschungszentrum Jülich
|b 0
|k FZJ
913 1 _ |0 G:(DE-HGF)POF3-553
|1 G:(DE-HGF)POF3-550
|2 G:(DE-HGF)POF3-500
|3 G:(DE-HGF)POF3
|4 G:(DE-HGF)POF
|a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|v Physical Basis of Diseases
|x 0
914 1 _ |y 2017
915 _ _ |0 StatID:(DE-HGF)0510
|2 StatID
|a OpenAccess
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 1 _ |a APC
980 1 _ |a FullTexts
980 _ _ |a comm
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a APC
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21